Euvichol-Plus Special Precautions

As with any vaccine, immunization with Euvichol-Plus may not protect 100% of susceptible persons.
As with all vaccines, appropriate medical treatment should always be readily available in case of a rare event of anaphylactic reactions following the administration of the vaccine. For this reason, it is recommended that the person should remain under medical supervision for at least 30 minutes after vaccination.
This vaccine contains residual formaldehyde. Caution should be taken in subjects with known hypersensitivity to formaldehyde.
The safety and immune response of Euvichol-Plus has not been clinically evaluated in individual with HIV/AIDS.
No specific clinical study has been conducted to evaluate the efficacy and safety of Euvichol-Plus in pregnant and lactation women. Therefore, the vaccine is not recommended for use in pregnancy.
No clinical study has been performed to evaluate the efficacy and safety of Euvichol-Plus in infants (less than 1 year of age). Therefore, the vaccine is not recommended for use in infants.